you, us. joining all Pete, you and Thank for thank
one to response a and therapy inhibitor strong setting leukemia confidence is is ziftomenib on best-in-class enrollment Our in of pace in the More in conviction reinforced just by of menin the that its potential registration-directed the moment. a our rapid increase. relapsed/refractory targeted This reported be for trial. of to in highest continues the and by supported rates complete
at durable European also of primarily update by to Hematology Phase ziftomenib, forward month. remissions single-agent Association next and by We're the encouraged I the an sharing activity our Congress in trial, driven we look
mutant in our with AML. NPMX of in to showed these recently glimpse co-mutated significant ziftomenib a data and relapsed heavily demonstrate patients abstract, got activity released continues You've that pretreated clinical refractory which
X X.X is of is a approximately the X count data time the achieved at the follow-up tolerated abstract of of months of months. a recovery. well the manageable. median of were complete cutoff, effect differentiation cutoff. X syndrome responses Ziftomenib median As ongoing recommended of XX data full XX NPMX January patients response patients still duration showed The with treated and at of dose Phase with X on-target
reporting evolving We as are these excited an of by to April cutoff. data, we early look updated data forward and data
the patients. X Phase announced on NPMX relapsed momentum indication of continued activation Phase the in dosed our registration-directed building our Site Now or by data, refractory outperforming our in study first an trial registration-directed enrollment X the projections, patients February in mutant and ziftomenib surrounding in enthusiasm AML. we generated were investigators of ziftomenib and that are positive among our
which approximately new patients unmet a chemotherapy. AML cases As significant reminder, for becomes mutant targeted for after prognosis disease therapy of relapsed exists. the annually X Once of approximately accounts need survival AML no for AML XX% with poor, mutant of an months refractory, overall represents NPMX approved a initial NPMX and particularly the or is disease
notably co-mutations compounded co-mutations, our patients achieved trial such AML at with Phase is these response complete FLTX full inhibitors. even prior treatment after of I'm activity with prior A rate and/or response a Ziftomenib failure complete rate more NPMX of IDH and/or a or NPMX-mutant count XX% makes with failed further AML sorry, targeted ziftomenib, have the with for IDH I mutant XXX targeted striking. full FLTX in who therapies FLTX, count clinical had whom of as IDH milligrams X/X recovery all CR of
data our of mutant remissions mutations, multiple We're as patient minimal a as achieved cell DNMTXA, and January with following CR a potential cycles stem disease Ziftomenib on remains prior code ziftomenib residual who drive XX also no with cutoff. the trial durable transplants for evidence entered with and impressed including to more the for X monotherapy, XX NPMX of than additional
for should We we're belief driven and to of broaden once-daily combination these uniquely several administration current predicted addressable series no dosing advantages, evidence drug-induced studies adverse that prolongation, to including patient no combination convenient is efforts oral In drug-drug advance population. of QTC positioned strategies. interactions care. with key This enable Ziftomenivisim by the competitive of to significantly with standards Ziftomenib a our preparing monotherapy, parallel initiate is believe
Our the and ziftomenib COMET with to of working in XXX care initiate standards evaluate is including to and team trials AML. populations, both earlier diligently multiple across current combination NPMX COMTXXX lines and therapy of in mutant patient KMTXA-rearranged
studies and ziftomenib Phase activity key in designed plus tolerability X We've assess X antileukemic venetoclax FLTX of regimens gilteritinib regimen such of and inhibitor X. combination the azacitidine, safety, the with and the to chemotherapy as
with value, therapy represent Our namely those approach the greatest used safely regimens inhibitor unmet commercial venetoclax the be regimens. need to potential that and combinations is combined ziftomenib then medical FLTX as foundational and largest commonly can containing a prioritize that various to establish and combinations
Notably, mutant up FLTX AML patients exhibit the in to also of co-mutations NPMX gene. half
that menin Given ideal the ziftomenib, the a group safety believe of FLTX to profile inhibitors represents of may XX% population, approximately we inhibitor be AML. difficult-to-treat to with address this it combine
at our emerging confidence data and menin to upcoming our team's patients studies, our We're support evidence with to the coupled IDH site excited to for in rational of syndrome will first combination as multiple this we're of proud body We've to believe in a mitigate growing and with best-in-class quarter. that studies inhibitor. execution of value Their clinical combination very the our track in ziftomenib leukemias. presentation very of of the been with We the of our patients more about has forward enthusiasm, differentiation dose combination in reinforce the for unlock approaches ziftomenib azacitidine. We as population COMET-XXX, We're activation the inhibitors of rearranged look EHA. in development KMTXA first lines sharing also begun grateful investigators. demonstrated help these and continued the on studies further acute previously at potential for
attention our to our turn transferase farnesyl program. let's Now inhibitor
in of solid years, several development to certain pioneered therapy large emergence past indications. FTIs to of combination targeted agents delay prevent the the resistance as Over we've or tumor of classes
solid demonstrated emerges invariably resistance almost range which Although clinical over across meaningful adaptive limits sustained tumors, therapies therapies to time, targeted ability have of targeted benefit. clinical the of a activity drive
that clinical the inhibitors SDIs targeted well body data We multiple preclinical have as EGFR of generated inhibitors. of support a including as classes therapies, PIX-kinase growing and combination of with
we use April, of the encouraging Meeting, preclinical which FTIs supports therapy. in American combination targeted of classes potential for Annual at presented X Research distinct the Association data Cancer In with additional
cell first cell and axitinib of carcinoma. of The tipifarnib revealed cell xenograft anti-angiogenic care renal models X and synergy between standard TKI, posters robust the clear in of patient-derived
The regression second therapy. sotorasib to KRAS multiple inhibitor of lung addition adagrasib tipifarnib non-small of or cell models either poster resistant the cancer through of reported
enhanced as address innate mechanisms targeted as for well FDIs of drive and antitumor activity adaptive resistance These promising both preclinical data illustrate to the potential to therapies.
in cell In of application strongly FTI, for as renal January, to lung new to announce these FDA carcinoma the clearance rationale KO-XXXX data we KRAS our this cell clear tumors, our addition, drug as investigational well we program. solid GXXC were pleased our next-generation inhibitors with treatment for support TKIs in mutant cell KO-XXXX believe non-small next for advanced important step of cancer. In an combine
solid patients as KOXXXX we the in escalation first intend to startup, escalation dose later to X antitumor safety, evaluate plan dose monotherapy, Concurrent also we tumors. in Phase FIT-XXX and We're we're escalation of in in FIT-XXX. which KO-XXXX forward dose to we combination a study dosing activity Now preliminary this study, look in advanced the and year. now with calling evaluate tolerability cohorts
patient observed response evaluate combination kinase activity HNSCC. potential to case, by also dose-limiting squamous the half therapy, alpelisib, preliminary We reported we optimal alpelisib combine to in patients with no to encouraged the with very all toxicities on PIX ongoing to by HN to cell Meanwhile, carcinoma a active including this in combination in date. PIKXCA address tipifarnib of durable the metastatic with dose a our to partial continue tonsil. tipifarnib biologically mutated pleased recurrent current that We're in remain track trial, in inhibitor, ability determine with another targeted a the alpha mid-XXXX. with up We're has of and our
therapeutic has tumor renal the increasingly we We large as of indications of inhibition, carcinoma challenging, value to opportunity the transferase address solid colorectal and farnesyl the as potential to cancers cell and well system. continue such potential that lung but commercial as believe substantial unlock
value potential we significant the care menin operational shareholders. confident have and programs our our believe with health We're create providers financial As and and we experience have value. inhibitor FTI leadership, program, patients, for that resources to realize to
call turn Doyle to over discussion for financial results. Tom that, the our now I'll a of With
